OKT3 monoclonal antibody in heart transplantation.
OKT3 monoclonal antibody (OKT3) has already proved to be a valuable edition to the immunosuppression armamentarium available in cardiac transplantation. It is highly effective in treating refractory rejection, where approximately 90% of subjects may be salvaged. It may be even more valuable in prophylaxis, where in combination with an antibody suppression strategy and low-dose, "delayed" cyclosporine it appears to afford near complete protection against rejection. Moreover, OKT3-based prophylaxis seems to impact favorably on the rejection rate after the prophylaxis course has been completed. Adverse reactions are common and generally manageable, although occasional serious clinical events do occur.
Bristow
M R
MR
Cardiology Division, University of Utah School of Medicine, Salt Lake City 84132.
Gilbert
E M
EM
O'Connell
J B
JB
Renlund
D G
DG
Watson
F S
FS
Hammond
E
E
Lee
R G
RG
Menlove
R
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D014184:Transplantation, Homologous; D014589:Utah
D000911:Antibodies, Monoclonal